We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23
Avg Time Held Equity + Options
6.9 quarters
Top 10 Avg Time Held Equity + Options
4.1 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
7.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
4.5 quarters

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX icon
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MNPR icon
76
Monopar Therapeutics
MNPR
$486M
$14.6M 0.27%
+157,423
New +$9.75M
2026 Q2
0 quarters
TVTX icon
77
Travere Therapeutics
TVTX
$5.06B
$14.4M 0.27%
+253,000
New +$11.2M
2026 Q2
0 quarters
TSHA icon
78
Taysha Gene Therapies
TSHA
$1.17B
$13.6M 0.25%
+2,000,000
New +$11.8M
2026 Q2
0 quarters
BIIB icon
79
Biogen
BIIB
$34B
$13.3M 0.25%
61,600
– –
2026 Q1
1 quarter
RVMD icon
80
Revolution Medicines
RVMD
$41.7B
$13.2M 0.24%
70,500
+18,500
+36% +$2.7M
2025 Q4
2 quarters
DNTH icon
81
Dianthus Therapeutics
DNTH
$4.26B
$11.2M 0.21%
+115,000
New +$10M
2026 Q2
0 quarters
SPRB icon
82
Spruce Biosciences
SPRB
$113M
$10.8M 0.2%
+200,000
New +$11.2M
2026 Q2
0 quarters
LFST icon
83
Lifestance Health
LFST
$4.7B
$10.1M 0.19%
947,400
+447,400
+89% +$3.46M
2026 Q1
1 quarter
RVMD icon
84
CALL
Revolution Medicines
RVMD
$41.7B
$9.36M 0.17%
+50,000
New +$7.3M
2026 Q2
0 quarters
ERAS icon
85
Erasca
ERAS
$5.14B
$9.08M 0.17%
+495,900
New +$7.09M
2026 Q2
0 quarters
TARA icon
86
Protara Therapeutics
TARA
$152M
$8.48M 0.16%
+2,220,000
New +$10.6M
2026 Q2
0 quarters
KROS icon
87
Keros Therapeutics
KROS
$220M
$8.12M 0.15%
759,155
– –
2020 Q2
24 quarters
JANX icon
88
Janux Therapeutics
JANX
$1.04B
$8.06M 0.15%
524,700
-458,900
-47% -$6.65M
2021 Q2
20 quarters
TECX icon
89
Tectonic Therapeutic
TECX
$413M
$7.79M 0.14%
226,600
– –
2025 Q4
2 quarters
ACET icon
90
Adicet Bio
ACET
$47.2M
$7.3M 0.14%
844,787
-183,157
-18% -$1.44M
2018 Q1
33 quarters
PHVS icon
91
Pharvaris
PHVS
$2.1B
$7.1M 0.13%
205,400
– –
2025 Q4
2 quarters
ANRO icon
92
Alto Neuroscience
ANRO
$861M
$6.8M 0.13%
257,852
+90,352
+54% +$2.09M
2024 Q4
6 quarters
ZNTL icon
93
Zentalis Pharmaceuticals
ZNTL
$224M
$6.74M 0.13%
+1,390,576
New +$5.55M
2026 Q2
0 quarters
DRUG icon
94
Bright Minds Biosciences
DRUG
$518M
$6.53M 0.12%
93,000
+53,000
+133% +$4.16M
2026 Q1
1 quarter
PVLA icon
95
CALL
Palvella Therapeutics
PVLA
$1.79B
$6.11M 0.11%
40,000
-10,000
-20% -$1.21M
2026 Q1
1 quarter
ALXO icon
96
ALX Oncology
ALXO
$126M
$5.93M 0.11%
2,866,256
– –
2026 Q1
1 quarter
XLO icon
97
Xilio Therapeutics
XLO
$59.3M
$5.67M 0.11%
+592,300
New +$4.95M
2026 Q2
0 quarters
BCAX icon
98
Bicara Therapeutics
BCAX
$1.15B
$5.67M 0.11%
191,100
-476,200
-71% -$10.6M
2025 Q4
2 quarters
IMA icon
99
ImageneBio Inc
IMA
$47.4M
$5.36M 0.1%
909,269
+530,713
+140% +$3M
2021 Q1
21 quarters
PTGX icon
100
Protagonist Therapeutics
PTGX
$8.96B
$5.16M 0.1%
42,100
– –
2025 Q4
2 quarters
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.